Process for the production of a reversibly inactive acidified plasmin composition

US7544500B2 · kind B2 · utility

Assignee

• Talecris Biotherapeutics, Inc. · US

Inventors

• Rita T. Bradley · Cary, US
• Scott A. Cook · Ballwin, US
• Christopher A. Dadd · Cary, US
• Jonathan D. Kent · Holly Springs, US
• Marina Korneyeva · Raleigh, US
• Valery Novokhatny · Raleigh, US
• James Rebbeor · Garner, US
• Christopher J. Stenland · Stanwood, US
• Jonathan S. Strauss · Los Angeles, US
• Jarrett Terry · Raleigh, US
• Jeffrey A. Yuziuk · Garner, US

Key dates

• Filing date: Oct 23, 2003
• Grant date: Jun 9, 2009
• Expiry date: Jul 21, 2025

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61K47/26
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Disclosed is both a process for producing a reversibly inactive acidified plasmin by activating plasminogen and a process for producing a purified plasminogen. The produced plasmin is isolated and stored with a low pH-buffering capacity agent to provide a substantially stable formulation. The purified plasminogen is typically purified from a fraction obtained in the separation of immunoglobulin from Fraction II+III chromatographic process and eluted at a low pH. The reversibly inactive acidified plasmin may be used in the administration of a thrombolytic therapy.